Sulfones

• 

  Subject Areas on Research

  • A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. 
  • A nuclear factor-kappaB inhibitor BAY11-7082 inhibits interactions between human endothelial cells, T cells, and monocytes. 
  • ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. 
  • Acute dysphonia secondary to vocal fold hemorrhage after vardenafil use. 
  • Acute urinary retention associated with the use of cyclooxygenase-2 inhibitors. 
  • Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. 
  • Balancing the cyclooxygenase portfolio. 
  • Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. 
  • Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. 
  • Co-regulation of nuclear respiratory factor-1 by NFkappaB and CREB links LPS-induced inflammation to mitochondrial biogenesis. 
  • Compensatory hypertrophy induced by ventricular cardiomyocyte-specific COX-2 expression in mice. 
  • Control of protein-ligand recognition using a stimuli-responsive polymer. 
  • Controlled release of etoricoxib from poly(ester urea) films for post-operative pain management. 
  • Determination of fasiglifam-induced liver toxicity: Insights from the data monitoring committee of the fasiglifam clinical trials program. 
  • Direct allosteric regulation between the GAF domain and catalytic domain of photoreceptor phosphodiesterase PDE6. 
  • Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. 
  • Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs. 
  • ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. 
  • Factor Xa induces tissue factor expression in endothelial cells by P44/42 MAPK and NF-κB-dependent pathways. 
  • Hepatocyte growth factor enhances death receptor-induced apoptosis by up-regulating DR5. 
  • How direct-to-consumer television advertising for osteoarthritis drugs affects physicians' prescribing behavior. 
  • Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis. 
  • Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. 
  • Induction of Neuroinflammation and Neurotoxicity by Synthetic Hemozoin. 
  • Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. 
  • Mammalian chymotrypsin-like enzymes. Comparative reactivities of rat mast cell proteases, human and dog skin chymases, and human cathepsin G with peptide 4-nitroanilide substrates and with peptide chloromethyl ketone and sulfonyl fluoride inhibitors. 
  • Meibomian gland dysfunction is suppressed via selective inhibition of immune responses by topical LFA-1/ICAM antagonism with lifitegrast in the allergic eye disease (AED) model. 
  • NFκB-mediated CXCL1 production in spinal cord astrocytes contributes to the maintenance of bone cancer pain in mice. 
  • Newer pharmacologic alternatives for erectile dysfunction. 
  • Nitric oxide-releasing polymeric microspheres improve diabetes-related erectile dysfunction. 
  • Nonsteroidal anti-inflammatory drugs and acetaminophen in the treatment of an acute muscle injury. 
  • Nucleophilic addition of organozinc reagents to 2-sulfonyl cyclic ethers: stereoselective synthesis of manassantins A and B. 
  • PPARβ/δ selectively regulates phenotypic features of age-related macular degeneration. 
  • PTEN reconstitution alters glioma responses to c-Met pathway inhibition. 
  • Patient detection of a drug dispensing error by use of physician-provided drug samples. 
  • Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. 
  • Phenylmethylsulfonyl fluoride protects rats from Mipafox-induced delayed neuropathy. 
  • PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design. 
  • Probing of the cis-5-phenyl proline scaffold as a platform for the synthesis of mechanism-based inhibitors of the Staphylococcus aureus sortase SrtA isoform. 
  • Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003. 
  • Prostaglandin-mediated effects in early canine corpus luteum: In vivo effects on vascular and immune factors. 
  • Pyoderma gangrenosum, altered delayed hypersensitivity and polyarthritis. 
  • Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. 
  • Reduced spontaneous relaxation in immature guinea pig airway smooth muscle is associated with increased prostanoid release. 
  • Relationship between cytochrome P450 2E1 and acetone catabolism in rats as studied with diallyl sulfide as an inhibitor. 
  • Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. 
  • Retinal effects of 6 months of daily use of tadalafil or sildenafil. 
  • Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. 
  • Role of prostacyclin in the cardiovascular response to thromboxane A2. 
  • Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. 
  • Sildenafil exposure and hemodynamic effect after Fontan surgery. 
  • Sildenafil exposure and hemodynamic effect after stage II single-ventricle surgery. 
  • Sildenafil improves walk distance in idiopathic pulmonary fibrosis. 
  • Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. 
  • Steroids LXXVI. Stereospecific formation of alpha- and beta-epoxides in the reaction of dimethylsulfonium methylide and dimethylsulfoxonium methylide with dihydrotestosterone. 
  • Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. 
  • Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx). 
  • The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options. 
  • The combination of theophylline and endothelin receptor antagonism improves exercise performance of rats under simulated high altitude. 
  • The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. 
  • The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. 
  • The lipopolysaccharide barrier: correlation of antibiotic susceptibility with antibiotic permeability and fluorescent probe binding kinetics. 
  • Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. 
  • Vascular endothelial growth factor and dexamethasone release from nonfouling sensor coatings affect the foreign body response. 
  • Vinyl sulfones: inhibitors of SrtA, a transpeptidase required for cell wall protein anchoring and virulence in Staphylococcus aureus. 
  • What about celebrex? 
  • X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor. 
• 

  Keywords of People

  • Barker, Piers Christopher Andrew, Professor of Pediatrics, Pediatrics, Cardiology
  • Cohen-Wolkowiez, Michael, Kiser-Arena Distinguished Professor, Pediatrics, Infectious Diseases
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology